Loading...
•
Sep 30, 2022
Humacyte Q3 2022 Earnings Report
Humacyte's third quarter 2022 financial results were announced, and the company highlighted progress in clinical development and corporate advancements.
Key Takeaways
Humacyte reported $31 thousand in revenue for Q3 2022, primarily from grants. The company's net loss was $25.3 million, and they had $171.7 million in cash, cash equivalents, and short-term investments as of September 30, 2022. They anticipate filing their BLA in mid 2023.
Plans to file a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for vascular trauma in mid 2023.
Initiated a research partnership with the Diabetes Research Institute (DRI) to facilitate development of the Biovascular Pancreas (BVP) for severe type 1 diabetes.
Enrollment is nearing completion in Phase 3 trial of the HAV for arteriovenous (AV) access in hemodialysis patients.
Continued to strengthen relationship with global partner and shareholder Fresenius Medical Care.
Forward Guidance
Humacyte believes that its cash, cash equivalents and short-term investments are adequate to fund operations through 2024, past the Company’s current expected timeline for potential approval of the HAV in vascular trauma.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...